Abstract
Mutations and fusions of RET (rearranged during transfection) gene are detected in a few common types of tumors including thyroid or non-small cells lung cancers. Multiple kinase inhibitors (MKIs) do not show spectacular effectiveness in patients with RET-altered tumors. Hence, recently, two novel RET-specific inhibitors were registered in the US and in Europe. Selpercatinib and pralsetinib showed high efficacy in clinical trials, with fewer adverse effects, in comparison to previously used MKIs. However, the effectiveness of these new drugs may be reduced by the emergence of resistance mutations in RET gene and activation of different activating signaling pathways. This review presents the function of the normal RET receptor, types of molecular disturbances of the RET gene in patients with various cancers, methods of detecting these abnormalities, and the effectiveness of modern anticancer therapies (ranging from immunotherapies, through MKIs, to RET-specific inhibitors).
Reference112 articles.
1. Esteban-Villarrubia, J., Soto-Castillo, J.J., Pozas, J., San Román-Gil, M., Orejana-Martín, I., Torres-Jiménez, J., Carrato, A., Alonso-Gordoa, T., and Molina-Cerrillo, J. Tyrosine Kinase Receptors in Oncology. Int. J. Mol. Sci., 2020. 21.
2. Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020);Huang;J. Hematol. Oncol.,2020
3. RET Receptor Signaling: Function in Development, Metabolic Disease, and Cancer;Takahashi;Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.,2022
4. RET Tyrosine Kinase Signaling in Development and Cancer;Arighi;Cytokine Growth Factor Rev.,2005
5. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients;Kato;Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献